D&A at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's D&A?
- Ionis Pharmaceuticals (IONS) reported D&A of $3.3M in Q1 2026.
- How has Ionis Pharmaceuticals's D&A changed year-over-year?
- Ionis Pharmaceuticals's D&A increased by 48.2% year-over-year, from $2.23M to $3.3M.
- What is the long-term trend for Ionis Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's D&A has grown at a -10.3% compound annual growth rate (CAGR), from $15.49M to $10.01M.
- What does D&A mean?
- The non-cash expense for the wear and tear of physical assets and the expiration of intangible assets.
- How do you interpret D&A?
- Stable levels indicate consistent capital investment, while significant changes may reflect shifts in the asset base or impairment events.
- How does D&A compare across companies?
- Varies by capital intensity; biotech firms typically have lower depreciation than manufacturing peers.